跳至主要内容
临床试验/EUCTR2012-001131-31-DK
EUCTR2012-001131-31-DK进行中(未招募)1 期

Effekts of nebivolol on the nitric oxide system in patients with essentiel hypertension - NEBI

Department of Medical Research0 个研究点目标入组 25 人开始时间: 2012年6月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Men and women
  • Age 40-70 years
  • Ambulatory blood pressure > 135 mmHg systolic and/or 85 mmHg diastolic in daytime during amlodipine treatment with either 5 or 10 mg
  • Informed consent
  • Fertiel women must take contraception
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • Diabetes mellitus
  • eGFR < 30
  • Albuminuria > 1,5 g/L
  • Renografi indicating sekundary hypertension
  • clinical signs of pheoocromocyta eller abnormal p-metanefrin.
  • Clinical important signs of lung, heart, liver or thyroid disease l
  • Clinical important abnormalities in screening blood samples and ECG
  • Clinical important hypokalimia
  • Clinical important abnormalities in plasma calcium
  • Neplastic diseases
  • Alcoholabuse
  • Drug or medical abuse
  • Pregnancy or nursing
  • Intolerans towards nebivolol
  • Bloddonationwithin a month
  • Uacceptable side effects to amlodipine
  • Ambulatory BP above 170/105 mmHg on hightest dose amlodipine 10mg)

研究者

相似试验

Effekts of nebivolol on the nitric oxide system in... | 临床试验